Received Mar 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 5JX2E | — |
seventeen year old patient received an adult dose of Engerix-B; seventeen year old patient received an adult dose of Engerix-B; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 18-year-old male patient who received HBV (Engerix B adult) (batch number 5JX2E, expiry date 14-DEC-2026) for prophylaxis. On 25-NOV-2024, the patient received Engerix B adult. On 25-NOV-2024, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: seventeen year old patient received an adult dose of Engerix-B) and overdose (Verbatim: seventeen year old patient received an adult dose of Engerix-B). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-FEB-2025 The reporter reported that a seventeen year old patient received an adult dose of Engerix B last year, which led to adult product administered to child and overdose. The reporter added now this patient was 18 years old and asked if the patient needs to receive another dose, and wanted to know was the patient covered.